LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS

Dupilumab Efficacy in Type 2 Asthmab Patients Receiving High Dose ICS

Bourdin A, et al.  Allergy. 2021;76(1):269–280

These materials are presented by Sanofi and Regeneron Medical for scientific exchange purposes only. Please refer to the package insert for full SmPC. Sanofi will not foster the application of our medicinal products in a way outside of the approved indication. Please always refer to the SmPC approved in your country before prescribing dupilumab. ^aPlease see manuscript for full details. ^bType 2-high asthma subgroups include patients with baseline blood EOS ≥150 μL or FeNO ≥25 ppb. ^cHigh dose ICS >1000 μg/day.ACQ-5, 5-item Asthma Control Questionnaire; CI, confidence interval; EOS, eosinophil; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; LS, least squares; ppb, parts per billion; Pre-BD FEV1, pre bronchodilator forced expiratory volume in 1 second; q2w, every 2 weeks; SE, standard error; SmPC, Summary of Product Characteristics.